Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Gets $2M Loan

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems has entered into a $2 million loan agreement with Oxford Finance Corp., the Fremont, Calif.-based firm disclosed in a filing with the US Securities and Exchange Commission today.

The agreement was effective Dec. 7, pursuant to a secured promissory note. The note will accrue at a fixed rate of roughly 13 percent.

In connection with the loan, WaferGen issued to Oxford a warrant to purchase 95,368 of the firm's common stock. The warrant is exercisable immediately at a price of $1.468 per share and expires in five years.

WaferGen's stock closed at $1.27 in Monday trade on the OTC Bulletin Board.

The firm said that it intends to use the loan for general corporate purposes.

Last month, WaferGen reported third-quarter revenues of $633,000, as a result of the summer launch of its SmartChip Real-Time PCR System. The firm finished its quarter ended Sept. 30, with $4.4 million in cash and cash equivalents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more